Franklin’s XRP ETF Buys $2.25 Million as Bitwise’s Fund Sells: Is Wall Street Losing Interest in XRP, or Just Waiting?
U.S. spot XRP ETFs took in a net $708,510 on Wednesday, October 21, their first inflow in a week, as Franklin Templeton’s XRPZ bought $2.25 million of XRP. Bitwise XRP ETF lost $1.55 million. Two empty days came before it. Most of October has looked the same. That is the quiet side of this week’s XRP news.
On the regulatory side, Ripple submitted a letter on Tuesday supporting the SEC’s proposed Regulation Crypto Assets. Chief legal officer Stuart Alderoty wrote on X that Ripple “spent more than $150 million to get clarity” in its court fight. A final rule has no date yet.
The XRP price is $1.33, down 2.3% in 24 hours after a rejection near $1.40 on Tuesday. So who is still buying the XRP ETFs, and which levels matter for the price?
JUST IN: Franklin ETF clients buy $2.25 million worth or $XRP. pic.twitter.com/hYXY395ekf
Very little, and mostly through one fund. Over the ten trading days from October 8, the five spot XRP ETFs took in a net $7 million, and $8.17 million of that came on the first day. Half of those sessions recorded no flows at all.
Franklin is the steady buyer. XRPZ took in $14.06 million across three days in that stretch. Bitwise’s fund, still the largest by total inflows at $680 million, lost $4.56 million over the same days, and Canary’s XRPC shed $2.47 million on October 16.
The week of October 12 to 16 ended with $1.83 million of net outflows, breaking a 13-week run of inflows. Compare that with Bitcoin: U.S. spot BTC funds took in about $1.07 billion from Monday to Wednesday this week, Farside data shows.
XRP ETFs aren’t being sold off; their total since launch in November 2025 still stands at $1.72 billion. Buyers just aren’t adding much at these prices.
XRP is stuck between two clear zones. Above, $1.37 is the wall: a daily swing high at $1.3661 sits just under the 50-day and 200-day EMAs, which crossed at $1.3742 and $1.3747 on the daily chart. Tuesday’s high near $1.40 is the line past it.
Below, $1.31 is the first support, the last daily swing low at $1.3098 and only two cents under today’s price. If it gives way, the next floor is $1.25, where buyers stepped in on October 18.
A daily close above $1.3747 would put XRP back above both moving averages and bring $1.40 into reach. A close below $1.31 points to a retest of $1.25.
Franklin keeps buying, a few million at a time. The next XRP news that matters is whether the other four funds join in before $1.31 is tested.
Follow 99Bitcoins on X For the Latest Market Updates and Subscribe on YouTube For Daily Expert Market Analysis.
Established in 2013, 99Bitcoins' team members have been crypto experts since Bitcoin’s early days.
Alex is a seasoned cryptocurrency trader and market analyst with over seven years of active experience in the digital asset space. Since entering the markets in 2017, Alex has specialized in identifying emerging "meta" trends and high-volatility narratives. Notably, Alex... Read More
Asanat Analysis — Why it matters
Franklin Templeton's sustained accumulation through XRPZ contrasts sharply with Bitwise's redemptions, signaling divergent institutional appetites rather than sector-wide disinterest. Franklin's $2.25M buy during a period of net inflows suggests conviction-based positioning, while Bitwise's $1.55M outflow may reflect either profit-taking after XRP's recent run or portfolio rebalancing unrelated to XRP fundamentals. The net positive inflow ($708k) masks significant internal rotation—a pattern typical during consolidation phases when large holders test conviction.
Flat ETF flows in October contrast with XRP's recent narrative catalysts (Ripple's regulatory clarity, institutional banking integrations). This suggests Wall Street is neither capitulating nor aggressively accumulating, but rather waiting for clear directional signals—either regulatory resolution on Ripple's pending cases or on-chain adoption metrics from announced partnerships. The absence of momentum inflows despite positive news indicates institutional buyers remain cautious on valuation or uncertain about XRP's differentiation versus layer-2 solutions and CBDCs.